目的 探討胸腺五肽聯(lián)合卡維地洛治療擴(kuò)張型心肌病的臨床療效。方法 選取2014年1月—2016年1月武漢航運(yùn)醫(yī)院收治的擴(kuò)張型心肌病患者68例，根據(jù)治療方案不同分為對照組和治療組，每組各34例。對照組口服卡維地洛片，初始劑量2.5 mg/次，2次/d，每1～2周遞增1次，最大劑量為25 mg/次，2次/d。治療組在對照組治療基礎(chǔ)上肌肉注射胸腺五肽注射液，10 mg與生理鹽水1 mL配伍，1次/d。4周為1個療程。2組均治療2個療程后進(jìn)行療效評價。觀察兩組的臨床療效，比較兩組患者治療前后6 min步行距離（6MWD）、B型尿鈉肽（BNP）、超敏C反應(yīng)蛋白（hs-CRP）、腫瘤壞死因子-α（TNF-α）水平的變化情況。結(jié)果 治療后，對照組和治療組的總有效率分別為67.65%、88.24%，兩組比較差異具有統(tǒng)計學(xué)意義（P< 0.05）。治療后，兩組6MWD顯著增多，血清hs-CRP、BNP、TNF-α水平均明顯下降，同組治療前后比較差異有統(tǒng)計學(xué)意義（P< 0.05）；治療后，治療組6MWD高于對照組，hs-CRP、BNP、TNF-α低于對照組，兩組比較差異有統(tǒng)計學(xué)意義（P< 0.05）。結(jié)論 胸腺五肽聯(lián)合卡維地洛治療擴(kuò)張型心肌病具有較好的臨床療效，可有效改善患者的臨床癥狀，降低機(jī)體的炎癥反應(yīng)，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical efficacy of thymopentin combined with carvedilol in treatment of dilated cardiomyopathy. Methods Patients (68 cases) with dilated cardiomyopathy in Wuhan Shipping Hospital from January 2016 to January 2017 were divided into control (34 cases) and treatment (34 cases) groups based on different treatments. Patients in the control group were po administered with Carvedilol Tablets, and the initial dosage was 2.5 mg/time, twice daily, increments every 1 to 2 weeks, the maximum dosage was 25 mg/time, twice daily. Patients in the treatment group were iv administered with Thymopentin Injection on the basis of the control group, 10 mg added into normal saline 1 mL, once daily. A course of treatment was 4 weeks, and patients in two groups were treated for 2 courses. After treatment, the clinical efficacies were evaluated, and 6MWD, BNP, hs-CRP, and TNF-α in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 67.65% and 88.24%, respectively, and there was difference between two groups (P < 0.05). After treatment, 6MWD was significantly increased, and hs-CRP, BNP, and TNF-α in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, 6MWD in the treatment group was higher than that in the control group, and hs-CRP, BNP, and TNF-α in the treatment group were significantly lower than those in the control group, and the difference was statistically significant between two groups (P < 0.05). Conclusion Thymopentin combined with carvedilol has clinical curative effect in treatment of dilated cardiomyopathy, and can effectively improve the clinical symptoms and reduce the inflammation of the body, which has a certain clinical application value.